[go: up one dir, main page]

MX2018001363A - Derivados del mononucleotido de nicotinamida y sus usos. - Google Patents

Derivados del mononucleotido de nicotinamida y sus usos.

Info

Publication number
MX2018001363A
MX2018001363A MX2018001363A MX2018001363A MX2018001363A MX 2018001363 A MX2018001363 A MX 2018001363A MX 2018001363 A MX2018001363 A MX 2018001363A MX 2018001363 A MX2018001363 A MX 2018001363A MX 2018001363 A MX2018001363 A MX 2018001363A
Authority
MX
Mexico
Prior art keywords
nicotinamide mononucleotide
relates
methods
derivatives
nicotinamide
Prior art date
Application number
MX2018001363A
Other languages
English (en)
Inventor
D Normington Karl
A Sinclair David
M Mckearin James
Szczepankiewicz Bruce
N Kremsky Jonathan
J Livingston David
Original Assignee
Metro Int Biotech Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57944181&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2018001363(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Metro Int Biotech Llc filed Critical Metro Int Biotech Llc
Publication of MX2018001363A publication Critical patent/MX2018001363A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
    • C07F9/6574—Esters of oxyacids of phosphorus
    • C07F9/65742—Esters of oxyacids of phosphorus non-condensed with carbocyclic rings or heterocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H11/00—Compounds containing saccharide radicals esterified by inorganic acids; Metal salts thereof
    • C07H11/04—Phosphates; Phosphites; Polyphosphates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/048—Pyridine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)

Abstract

La invención se refiere a composiciones de derivados del mononucleótido de nicotinamida y sus métodos de uso. La invención también se refiere a métodos para preparar derivados del mononucleótido de nicotinamida. La invención se refiere a composiciones farmacéuticas y suplementos nutricionales que contienen un derivado de mononucleótido de nicotinamida. La invención se refiere a métodos de uso derivados del mononucleótido de nicotinamida que promueven el incremento de niveles intracelulares de nicotinamida adenina dinucleótida (NAD+) en células y tejidos para tratar enfermedades y mejorar la supervivencia de células y tejidos.
MX2018001363A 2015-08-05 2016-08-05 Derivados del mononucleotido de nicotinamida y sus usos. MX2018001363A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562201447P 2015-08-05 2015-08-05
PCT/US2016/045855 WO2017024255A1 (en) 2015-08-05 2016-08-05 Nicotinamide mononucleotide derivatives and their uses

Publications (1)

Publication Number Publication Date
MX2018001363A true MX2018001363A (es) 2018-11-29

Family

ID=57944181

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018001363A MX2018001363A (es) 2015-08-05 2016-08-05 Derivados del mononucleotido de nicotinamida y sus usos.

Country Status (17)

Country Link
US (6) US9855289B2 (es)
EP (1) EP3331894B1 (es)
JP (1) JP6949002B6 (es)
KR (1) KR102354784B1 (es)
CN (1) CN108137639B (es)
AU (1) AU2016302005B2 (es)
BR (1) BR112018002168B1 (es)
CA (1) CA2994553C (es)
DK (1) DK3331894T3 (es)
EA (1) EA035664B1 (es)
ES (1) ES2862170T3 (es)
IL (1) IL257327B (es)
MX (1) MX2018001363A (es)
PL (1) PL3331894T3 (es)
PT (1) PT3331894T (es)
WO (1) WO2017024255A1 (es)
ZA (1) ZA201801196B (es)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3331894T3 (pl) 2015-08-05 2021-08-23 Metro International Biotech, Llc Pochodne mononukleotydu nikotynamidowego i ich zastosowania
GB2542881B (en) 2015-10-02 2020-01-01 Carr Andrew Crystal forms of ß-nicotinamide mononucleotide
US10611790B2 (en) 2015-11-02 2020-04-07 Mitobridge, Inc. Nicotinamide riboside and nicotinamide mononucleotide derivatives for use in the treatments of mitochondrial-related diseases
ES2948968T3 (es) 2016-04-20 2023-09-22 Chromadex Inc Uso del ribósido de ácido nicotínico o derivados del ribósido de nicotinamida, y derivados reducidos de los mismos, como precursores que aumentan el NAD++
US20200009170A1 (en) * 2016-09-13 2020-01-09 Megumi Tanaka Sleep display agent property and method for improving sleep disorders
WO2018236814A2 (en) * 2017-06-19 2018-12-27 Gangadhara Ganapati NICOTINAMIDE RIBOSID DERIVATIVES AND USES THEREOF
AU2019214858B2 (en) 2018-01-30 2023-02-02 Metro International Biotech, Llc Nicotinamide riboside analogs, pharmaceutical compositions, and uses thereof
CN112105718B (zh) * 2018-03-22 2024-10-18 东方酵母工业株式会社 多能干细胞分化促进剂
US10654883B2 (en) 2018-05-15 2020-05-19 Jumpstart Fertility Pty Ltd Inorganic salts of nicotinic acid mononucleotide as anti-aging agents
US11833167B2 (en) 2018-12-17 2023-12-05 Mitopower Llc Nicotinyl riboside compounds and their uses
US11491175B2 (en) 2019-02-25 2022-11-08 Celagenex Research (India) Pvt. Ltd. Synergistic bioactive compositions for enhancing cellular energy
US10618927B1 (en) 2019-03-22 2020-04-14 Metro International Biotech, Llc Compositions and methods for modulation of nicotinamide adenine dinucleotide
US11939348B2 (en) 2019-03-22 2024-03-26 Metro International Biotech, Llc Compositions comprising a phosphorus derivative of nicotinamide riboside and methods for modulation of nicotinamide adenine dinucleotide
JP2022534872A (ja) * 2019-06-05 2022-08-04 ソシエテ・デ・プロデュイ・ネスレ・エス・アー 肝疾患の治療のための還元型ニコチンアミドリボシド
EP4471042A3 (en) 2019-07-19 2025-03-05 Biosynth AG Method of making nicotinamide ribofuranoside salts, nicotinamide ribofuranoside salts as such, and uses thereof
CA3153239A1 (en) 2019-09-09 2021-03-18 Nuvamid Sa Use of nmn for the prevention and/or treatment of pain, and corresponding compositions
FR3100449B1 (fr) 2019-09-09 2022-08-26 Nuvamid Sa Utilisation de NMN pour la prévention et/ou le traitement de la douleur et compositions correspondantes
FR3102058A1 (fr) 2019-10-18 2021-04-23 Nuvamid Sa Utilisation de NMN pour la prévention et/ou le traitement de la polyarthrite rhumatoïde et compositions correspondantes
CN112823778B (zh) * 2019-11-21 2024-06-14 百瑞全球有限公司 毛发护理组合物及其制备方法
FR3103702B1 (fr) 2019-11-28 2022-02-11 Nuvamid Sa Utilisation de NMN pour la prévention et/ou le traitement de la spondylarthrite ankylosante et compositions correspondantes
FR3106056B1 (fr) 2020-01-13 2021-12-17 Nuvamid Utilisation de NMN pour la prévention et/ou le traitement d’une douleur articulaire induite par l’activité physique et compositions correspondantes
FR3107897B1 (fr) * 2020-03-06 2023-05-26 Nuvamid Sa Dérivés de nicotinamide mononucléotides
FR3108032B1 (fr) * 2020-03-12 2024-02-16 Nuvamid Sa Utilisation de NMN pour la prévention et/ou le traitement d’une douleur musculaire, ligamentaire ou tendineuse induite par l’activité physique et compositions correspondantes
FR3108031B1 (fr) 2020-03-12 2024-02-16 Nuvamid Sa Utilisation de NMN pour la prévention et/ou le traitement d’une douleur dorsale et compositions correspondantes
IL296817A (en) * 2020-03-30 2022-11-01 Oriental Yeast Co Ltd Chromosome stabilizing agent for stem cells
EP3901160A1 (en) * 2020-04-25 2021-10-27 Nuvamid SA Nicotinamide mononucleotide and nicotinamide riboside derivatives and use thereof in the treatment of viral infections and respiratory complications, in particular caused by influenzavirus or coronavirus
WO2021214299A1 (en) * 2020-04-24 2021-10-28 Nuvamid Sa Nicotinamide mononucleotide and nicotinamide riboside derivatives and use thereof in the treatment of viral infections and respiratory complications, in particular caused by influenzavirus or coronavirus
EP4114410A4 (en) * 2020-05-05 2023-09-13 Conagen Inc. PRODUCTION OF NMN AND ITS DERIVATIVES BY MICROBIAL PROCESSES
FR3110410A1 (fr) 2020-05-20 2021-11-26 Nuvamid Sa Compositions cosmétiques anti-âge comprenant de la NMN
US20230210746A1 (en) 2020-05-20 2023-07-06 Nuvamid Sa Anti-aging cosmetic compositions comprising nmn
FR3110836B1 (fr) 2020-05-29 2023-06-16 Nuvamid Utilisation de NMN pour réduire l’immunodépression et l’immunosénescence
CN111548383B (zh) * 2020-06-11 2023-04-18 湖南和泰康瑞生物技术有限公司 一种β-烟酰胺单核苷酸的工艺制备方法
CN111956670A (zh) * 2020-08-31 2020-11-20 杭州伊瑟奇生物科技有限公司 一种间充质干细胞及其活性因子复合物冻干品的制备方法
WO2022047779A1 (zh) * 2020-09-07 2022-03-10 音芙医药科技(上海)有限公司 烟酰胺单核苷酸在制备提高损伤皮肤肌膜中Na+-K+-ATP酶水平试剂中的应用
CN112094362B (zh) * 2020-09-29 2022-04-12 四川大学华西医院 烟酰胺核糖或单核苷酸类似物-大分子载体轭合物及制法和应用
WO2022094916A1 (zh) * 2020-11-06 2022-05-12 中国科学院深圳先进技术研究院 一种提高烟酰胺磷酸核糖转移酶活性的方法及其组合物
CN112500445B (zh) * 2020-12-04 2022-11-29 黄冈鲁班药业股份有限公司 β-烟酰胺核糖的制备方法
IT202100005054A1 (it) * 2021-03-04 2022-09-04 Azienda Ospedaliero Univ Di Parma Composto farmaceutico per l’uso in un trattamento terapeutico dell’infezione cronica da hbv e metodo per l’identificazione di linfociti esauriti
KR102633321B1 (ko) * 2021-05-11 2024-02-05 연세대학교 산학협력단 노인성 황반변성의 예방 또는 치료를 위한 약학 조성물
BR112023024712A2 (pt) 2021-05-27 2024-02-15 Metro Int Biotech Llc Sólidos cristalinos de mononucleotídeo de ácido nicotínico e ésteres dos mesmos e métodos de fabricação e uso
CN115304655B (zh) * 2021-11-23 2024-11-22 中立安(北京)医药科技有限公司 烟酰胺单核苷类衍生物及其制备方法和应用
WO2023119230A1 (en) 2021-12-22 2023-06-29 L'oreal Coagulation pathway and nicotinamide-adenine dinucleotide pathway modulating compositions and methods of their use
JP2025500336A (ja) 2021-12-22 2025-01-09 メトロ インターナショナル バイオテック，エルエルシー 炎症を治療するための組成物
CN114540283B (zh) * 2022-01-27 2023-10-20 中国农业科学院北京畜牧兽医研究所 用于牛体外胚胎生产的高效玻璃化冷冻方法
WO2023173196A1 (en) 2022-03-18 2023-09-21 Enveric Biosciences Canada Inc. C4-carboxylic acid-substituted tryptamine derivatives and methods of using
CN115611960A (zh) * 2022-11-18 2023-01-17 翔鹏(北京)生物科技有限公司 一种人体辅酶i前体的制备方法
CN118593362A (zh) * 2024-06-26 2024-09-06 山东福瑞达生物股份有限公司 一种nmn油悬液的制备方法与应用

Family Cites Families (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3201389A (en) 1962-09-24 1965-08-17 Kyowa Hakko Kogyo Kk Method for preparing ribonucleoside-5'-phosphates or their salts from ribonucleosides
US3451997A (en) 1965-11-30 1969-06-24 Kyowa Hakko Kogyo Kk Monothio-phosphate ester catalysis for preparation of ribonucleoside derivatives
US4411995A (en) 1981-09-28 1983-10-25 Massachusetts Institute Of Technology Synthesis of nicotinamide cofactors
US5318508A (en) 1991-03-15 1994-06-07 Elvira Osthold Nail corrective brace
EA200301204A1 (ru) 2001-04-30 2004-04-29 Тромсдорф ГмбХ унд Ко.КГ Арцнаймиттель Фармацевтически активные производные нуклеозида, способ их получения, их применение (варианты) и содержащая их фармацевтическая композиция, способ профилактики и/или лечения заболеваний и нарушений млекопитающих (варианты), комбинация лекарственных средств и ее применение (варианты)
US7977049B2 (en) 2002-08-09 2011-07-12 President And Fellows Of Harvard College Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
US20040224039A1 (en) 2003-02-12 2004-11-11 Donald Brucker Compositions and methods for the treatment of diseases and disorder associated with oxidative damage
CA2553542A1 (en) 2003-10-31 2005-04-30 Robarts Research Institute Methods and formulations for protecting cells, and for treating diseases and conditions by optimizing the intracellular concentration of nad
US7776326B2 (en) 2004-06-04 2010-08-17 Washington University Methods and compositions for treating neuropathies
US7998974B2 (en) 2005-03-03 2011-08-16 Sirtris Pharmaceuticals, Inc. Fused heterocyclic compounds and their use as sirtuin modulators
CA2610854A1 (en) 2005-03-30 2006-10-05 Sirtris Pharmaceuticals, Inc. Nicotinamide riboside and analogues thereof
US20070149466A1 (en) 2005-07-07 2007-06-28 Michael Milburn Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders
US7855289B2 (en) 2005-08-04 2010-12-21 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
JP2009504677A (ja) 2005-08-12 2009-02-05 メルク・エンド・カムパニー・インコーポレーテツド 新規２’−ｃ−メチル及び４’−ｃ−メチルヌクレオシド誘導体
JP5063878B2 (ja) 2005-08-30 2012-10-31 扶桑薬品工業株式会社 硫化水素塩を含有する消化器系疾患の予防／治療用組成物
CN101360421B (zh) 2005-11-18 2014-06-18 康乃尔研究基金会有限公司 烟酰核苷组合物及其使用方法
WO2007124447A2 (en) 2006-04-20 2007-11-01 Fred Hutchinson Cancer Research Center Use of chalcogenides for treating shock and other adverse conditions
US20080318892A1 (en) 2006-04-28 2008-12-25 John Geoffrey Pickering Methods and formulations for protecting cells, and for treating diseases and conditions by optimizing the intracellular concentration of nad
MX2009008022A (es) 2007-01-26 2009-12-11 Univ Washington Metodos y composiciones para tratar neuropatias.
TW200936146A (en) 2007-11-29 2009-09-01 Metabasis Therapeutics Inc Antiviral nucleoside compounds
CN101497638B (zh) * 2008-01-30 2012-09-26 中国科学院大连化学物理研究所 一种nad+类似物及其合成和应用
EA020659B1 (ru) 2008-04-23 2014-12-30 Джилид Сайэнс, Инк. 1'-замещённые карбануклеозидные аналоги для противовирусной терапии
US11219696B2 (en) 2008-12-19 2022-01-11 Nationwide Children's Hospital Delivery of polynucleotides using recombinant AAV9
CN101601679B (zh) 2009-03-17 2011-08-10 中国人民解放军第二军医大学 一种烟酰胺单核苷酸的应用
US20100297079A1 (en) * 2009-05-20 2010-11-25 Chimerix, Inc. Compounds, compositions and methods for treating viral infection
EP2558589A4 (en) 2010-04-15 2014-01-01 Glaxosmithkline Llc SIRTUIN ACTIVATORS AND ACTIVATION ASSAYS FOR THIS
TW201201815A (en) 2010-05-28 2012-01-16 Gilead Sciences Inc 1'-substituted-carba-nucleoside prodrugs for antiviral treatment
JP5663576B2 (ja) 2010-07-06 2015-02-04 秀則 上西 神経突起伸長剤
SG188367A1 (en) 2010-09-03 2013-04-30 Forma Tm Llc Novel compounds and compositions for the inhibition of nampt
JP6038792B2 (ja) 2010-09-03 2016-12-07 フォーマ ティーエム， エルエルシー． 癌などの疾患の治療のためのｎａｍｐｔ阻害剤としての４−｛［（ピリジン−３−イル−メチル）アミノカルボニル］アミノ｝ベンゼン−スルホン誘導体
EP2611778B1 (en) 2010-09-03 2015-08-05 Forma TM, LLC. Guanidine compounds and compositions for the inhibition of nampt
WO2012094343A1 (en) * 2011-01-05 2012-07-12 Trilink Biotechnologies Chemically substituted thermosensitive probes and cofactors for hot start ligation
US20140065099A1 (en) 2011-02-15 2014-03-06 Ecole Polytechnique Federale De Lausanne (Epfl) Methods of Treating Mitochondrial Dysfunction
US20120107888A1 (en) 2011-02-17 2012-05-03 Qteros, Inc. Modulation of fermentation products through vitamin supplementation
CN103717574B (zh) 2011-05-04 2017-02-22 福马Tm有限责任公司 用于抑制nampt的新化合物和组合物
US20120328526A1 (en) 2011-06-27 2012-12-27 University Of Maryland, Baltimore Modulation of Nad+ Activity in Neuropathophysiological Conditions and Uses Thereof
WO2013002879A1 (en) 2011-06-29 2013-01-03 President And Fellows Of Harvard College Small molecule cd38 inhibitors and methods of using same
US20130143835A1 (en) 2011-12-05 2013-06-06 Medivir Ab HCV Polymerase Inhibitors
WO2013127268A1 (en) 2012-03-02 2013-09-06 Genentech,Inc. Amido-benzyl sulfone and sulfonamide derivatives
WO2013127267A1 (en) 2012-03-02 2013-09-06 Genentech, Inc. Pyridinyl and pyrimidinyl sulfoxide and sulfone derivatives
WO2013130943A1 (en) 2012-03-02 2013-09-06 Genentech, Inc. Alkyl-and di-substituted amido-benzyl sulfonamide derivatives
SG10201701894SA (en) 2012-03-02 2017-05-30 Genentech Inc Amido-Benzyl Sulfone and Sulfoxide Derivatives
SG11201405056UA (en) 2012-03-02 2014-09-26 Genentech Inc Amido spirocyclic amide and sulfonamide derivatives
CA2873315A1 (en) 2012-05-22 2013-11-28 Idenix Pharamaceuticals, Inc. D-amino acid compounds for liver disease
WO2014014828A1 (en) 2012-07-16 2014-01-23 Cornell University Nicotinamide riboside to treat hearing loss
WO2014059034A2 (en) 2012-10-09 2014-04-17 President And Fellows Of Harvard College Nad biosynthesis and precursors for the treatment and prevention of cancer and proliferation
CN102876759A (zh) 2012-10-29 2013-01-16 尚科生物医药（上海）有限公司 尼克酰胺腺嘌呤二核苷酸的制备方法
WO2014074715A1 (en) 2012-11-07 2014-05-15 Genentech, Inc. Cyclopropyl amide derivatives
WO2014111906A1 (en) 2013-01-21 2014-07-24 Ecole Polytechnique Federale De Lausanne (Epfl) Bioluminescence imaging of small biomolecules
WO2014146044A1 (en) 2013-03-15 2014-09-18 Washington University Administration of nicotinamide mononucleotide in the treatment of disease
US20140271355A1 (en) 2013-03-15 2014-09-18 Sabre Intellectual Property Holdings Llc Apparatus and process for focused gas phase application of biocide
GB201313465D0 (en) 2013-07-29 2013-09-11 Queens University Of The Belfast Methods of preparing nicotinamide riboside and derivatives thereof
US20160287621A1 (en) 2013-11-06 2016-10-06 President And Fellows Of Harvard College Biological production of nad precursors and analogs
BR112016010422B1 (pt) 2013-11-12 2021-08-31 Ortho-Nutra, Llc Suplemento dietético e método de tratamento para melhorar o desempenho ou energia física em um indivíduo
US10398701B2 (en) 2013-11-12 2019-09-03 Ortho-Nutra, Llc Theacrine-based supplement and method of use thereof in a synergistic combination with caffeine
EP3068364B1 (en) 2013-11-14 2021-11-03 Metro Biotech NSW Pty Ltd Nad+ precursor selected from nmn, naad, namn, or a pharmaceutically acceptable salt thereof, for use in treating a side effect of chemotherapy and/or radiotherapy in a subject
CN104367587B (zh) 2013-12-06 2018-06-29 中国人民解放军第二军医大学 烟酰胺单核苷酸在制备促脑缺血后神经再生药物中的应用
US10301268B2 (en) 2014-03-13 2019-05-28 The Salk Institute For Biological Studies Analogs of fexaramine and methods of making and using
AU2015229055B2 (en) 2014-03-13 2019-09-12 Salk Institute For Biological Studies Analogs of fexaramine and methods of making and using
US20150258052A1 (en) 2014-03-13 2015-09-17 Salk Institute For Biological Studies Methods of using fexaramine and agents that increase sympathetic nervous system activity to promote browning of white adipose tissue
US10316054B2 (en) 2014-06-02 2019-06-11 Glaxosmithkline Intellectual Property (No. 2) Limited Preparation and use of crystalline beta-D-nicotinamide riboside
WO2015187649A1 (en) 2014-06-03 2015-12-10 Sulfagenix, Inc. Methods and compositions for treating nitric oxide deficiency disorders and related conditions
MX2016016071A (es) 2014-06-06 2017-07-11 Glaxosmithkline Intellectual Property (No 2) Ltd Analogos de ribosido de nicotinamida y composiciones farmaceuticas y usos de los mismos.
PL3670522T3 (pl) 2014-07-24 2022-02-21 W.R. Grace & Co. - Conn. Krystaliczna postać chlorku rybozydu nikotynamidu
US10653782B2 (en) 2014-11-25 2020-05-19 Nortwestern University Retroviral particles expressing Sirt1 embedded within PPCN
US20170326100A1 (en) 2014-12-09 2017-11-16 Amorepacific Corporation Composition for activating longevity gene
FI3268379T3 (fi) 2015-03-09 2023-12-15 Grace W R & Co Nikotiiniamidiribosidin kiteinen muoto
CN104817604B (zh) 2015-03-16 2017-08-04 邦泰生物工程(深圳)有限公司 一种β‑烟酰胺单核苷酸的纯化方法
EP3271456A1 (en) 2015-03-18 2018-01-24 The Regents of the University of California Methods of preventing and reversing stem cell aging
MX2017015496A (es) 2015-06-04 2018-08-01 Chromadex Inc Fosforilacion selectiva sin disolvente.
US20180177703A1 (en) 2015-06-25 2018-06-28 N.V. Perricone Llc Niacinamide Mononucleotide Formulations For Skin Aging
PL3331894T3 (pl) 2015-08-05 2021-08-23 Metro International Biotech, Llc Pochodne mononukleotydu nikotynamidowego i ich zastosowania
TW201713774A (zh) 2015-08-06 2017-04-16 Kohjin Life Sciences Co Ltd 含有β-菸鹼醯胺單核苷酸的酵母萃取物及其製造方法
GB2542881B (en) 2015-10-02 2020-01-01 Carr Andrew Crystal forms of ß-nicotinamide mononucleotide
SG11201802933YA (en) 2015-10-07 2018-05-30 Joel Huizenga Resetting biological pathways for defending against and repairing deterioration from human aging
US10611790B2 (en) 2015-11-02 2020-04-07 Mitobridge, Inc. Nicotinamide riboside and nicotinamide mononucleotide derivatives for use in the treatments of mitochondrial-related diseases
ES2812456T3 (es) 2015-12-21 2021-03-17 Showa Denko Kk Derivado de mononucleótido de nicotinamida y sal del mismo, método para producir el mismo, agente tópico, cosmético y aditivo alimentario
EP3187180A1 (en) 2015-12-28 2017-07-05 Ludwig-Maximilians-Universität München Adenosylhomocysteinase binding substances for medical use
WO2017145151A1 (en) 2016-02-23 2017-08-31 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Process for preparation of nicotinamide riboside (nr) and cosmetic composition comprising (nr and a phosphate-binding agent
CA3017254C (en) 2016-03-16 2023-08-22 ChromaDex Inc. B-vitamin and amino acid conjugates of nicotinoyl ribosides and reduced nicotinoyl ribosides, derivatives thereof, and methods of preparation thereof
ES2948968T3 (es) 2016-04-20 2023-09-22 Chromadex Inc Uso del ribósido de ácido nicotínico o derivados del ribósido de nicotinamida, y derivados reducidos de los mismos, como precursores que aumentan el NAD++
WO2017218580A1 (en) 2016-06-14 2017-12-21 Rejuvenation Therapeutics Corporation Synthetic methods for the preparation of nicotinamide riboside and related compounds
CN108026535B (zh) 2016-07-30 2021-04-27 邦泰生物工程(深圳)有限公司 一种制备烟酰胺单核苷酸的方法
CN107922952B (zh) 2016-07-30 2021-04-27 邦泰生物工程(深圳)有限公司 一种制备烟酰胺单核苷酸的方法
WO2018023205A1 (zh) 2016-07-30 2018-02-08 邦泰生物工程(深圳)有限公司 一种烟酰胺单核苷酸的纯化方法
US11040996B2 (en) 2016-07-30 2021-06-22 Bontac Bio-Engineering(Shenzhen) Co., Ltd Method for preparing nicotinamide mononucleotide (NMN)
CN107889504B (zh) 2016-07-30 2021-07-27 邦泰生物工程(深圳)有限公司 一种制备烟酰胺单核苷酸的方法
CN107889505B (zh) 2016-07-30 2021-05-25 邦泰生物工程(深圳)有限公司 一种制备烟酰胺单核苷酸的方法
WO2018047715A1 (ja) 2016-09-06 2018-03-15 協和発酵バイオ株式会社 β－ニコチンアミドモノヌクレオチドの結晶及びその製造方法
CN109691011B (zh) 2016-09-09 2022-06-14 日本电气株式会社 发送装置、接收装置、量子密钥分发方法和介质
ES2955713T3 (es) 2016-09-13 2023-12-05 Megumi Tanaka Agente de mejora de la función visual, y método para mejorar la función visual
US20200009170A1 (en) 2016-09-13 2020-01-09 Megumi Tanaka Sleep display agent property and method for improving sleep disorders
CN120463761A (zh) 2016-11-11 2025-08-12 英国贝尔法斯特女王大学 烟酰基核苷和还原的烟酰基核苷、其改性衍生物、磷酸化的类似物、腺苷二核苷酸共轭物、以及新颖结晶形式的有效且可规模化的合成
KR20190110547A (ko) 2016-12-21 2019-09-30 뉴사우스 이노베이션즈 피티와이 리미티드 혈관 밀도의 향상 방법
CN106755209B (zh) 2016-12-29 2021-07-23 苏州汉酶生物技术有限公司 一种酶法制备β-烟酰胺单核苷酸的方法
WO2018132833A1 (en) 2017-01-13 2018-07-19 The Regents Of The University Of Colorado, A Body Corporate Methods for treating hypertension and arterial stiffness
CN110446780B (zh) 2017-01-31 2024-01-09 东方酵母工业株式会社 多能干细胞增殖促进剂
JP6920071B2 (ja) 2017-02-16 2021-08-18 ワシントン・ユニバーシティＷａｓｈｉｎｇｔｏｎ Ｕｎｉｖｅｒｓｉｔｙ アディポネクチン分泌向上剤
HUE055521T2 (hu) 2017-04-05 2021-11-29 Univ Cornell Béta-nikotinát-észter nukleotidok és eljárás azok elõállítására
US20200368198A1 (en) 2017-07-31 2020-11-26 Newsouth Innovations Pty Limited Methods for increasing fertility
AU2019214858B2 (en) 2018-01-30 2023-02-02 Metro International Biotech, Llc Nicotinamide riboside analogs, pharmaceutical compositions, and uses thereof
US20210388018A1 (en) 2018-10-01 2021-12-16 Cornell University Methyl and ethyl nicotinate-riboside-5-phosphates, preparation thereof and methods of use thereof
JP2022512126A (ja) 2018-12-10 2022-02-02 クロマデックス，インコーポレイテッド ニコチノイルリボシド及びその誘導体の結晶形態、並びにその調製方法
US11939348B2 (en) 2019-03-22 2024-03-26 Metro International Biotech, Llc Compositions comprising a phosphorus derivative of nicotinamide riboside and methods for modulation of nicotinamide adenine dinucleotide
JP2022523864A (ja) 2019-03-22 2022-04-26 メトロ インターナショナル バイオテック，エルエルシー ニコチンアミドリボシドのリン誘導体を含む組成物及びニコチンアミドアデニンジヌクレオチドのモジュレーションのための方法
US10618927B1 (en) 2019-03-22 2020-04-14 Metro International Biotech, Llc Compositions and methods for modulation of nicotinamide adenine dinucleotide
US20230210746A1 (en) 2020-05-20 2023-07-06 Nuvamid Sa Anti-aging cosmetic compositions comprising nmn
BR112023024712A2 (pt) 2021-05-27 2024-02-15 Metro Int Biotech Llc Sólidos cristalinos de mononucleotídeo de ácido nicotínico e ésteres dos mesmos e métodos de fabricação e uso

Also Published As

Publication number Publication date
BR112018002168A2 (en) 2018-09-18
AU2016302005B2 (en) 2021-03-04
DK3331894T3 (da) 2021-03-22
US12485135B2 (en) 2025-12-02
US20240350523A1 (en) 2024-10-24
EA035664B1 (ru) 2020-07-23
CN108137639B (zh) 2021-10-08
US20200352966A1 (en) 2020-11-12
WO2017024255A1 (en) 2017-02-09
ES2862170T3 (es) 2021-10-07
EP3331894A4 (en) 2019-01-23
US20230158053A1 (en) 2023-05-25
CA2994553C (en) 2022-08-30
US20170290850A1 (en) 2017-10-12
BR112018002168B1 (pt) 2023-10-10
US9919003B2 (en) 2018-03-20
US9855289B2 (en) 2018-01-02
IL257327A (en) 2018-03-29
ZA201801196B (en) 2021-07-28
IL257327B (en) 2021-08-31
KR102354784B1 (ko) 2022-01-25
US11464796B2 (en) 2022-10-11
US20170189434A1 (en) 2017-07-06
US11878027B2 (en) 2024-01-23
US10548913B2 (en) 2020-02-04
CA2994553A1 (en) 2017-02-09
KR20180039658A (ko) 2018-04-18
EP3331894A1 (en) 2018-06-13
EP3331894B1 (en) 2021-02-17
JP6949002B6 (ja) 2021-11-17
JP2018522042A (ja) 2018-08-09
US20180147227A1 (en) 2018-05-31
JP6949002B2 (ja) 2021-10-13
AU2016302005A1 (en) 2018-03-08
PT3331894T (pt) 2021-04-07
PL3331894T3 (pl) 2021-08-23
EA201890435A1 (ru) 2018-09-28
CN108137639A (zh) 2018-06-08

Similar Documents

Publication Publication Date Title
MX2018001363A (es) Derivados del mononucleotido de nicotinamida y sus usos.
MX2017011851A (es) Composiciones de acido nicotinico ribosido o de nicotinamida ribosido, derivados reducidos de los mismos, y su uso.
MX2018012849A (es) Uso de derivados de ribósido de ácido nocotínico o ribósido de nicotinamida, y derivados reducidos de estos, como precursores de que incementan nad+.
ECSP20033467A (es) Compuestos macrocíclicos para tratar enfermedades
UY37435A (es) Pirrolidinas sustituidas y métodos para usarlas
CO2017008403A2 (es) Derivados de nucleósidos sustituidos útiles como agentes antineoplásicos
PH12017501191B1 (en) Quinazoline derivatives used to treat hiv
ZA201605979B (en) 4'-difluoromethyl substituted nucleoside derivatives as inhibitors of influenza rna replication
UY36265A (es) “derivados de pirrolo[2,3-d]pirimidina”.
MX2018005725A (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cancer.
CL2016003214A1 (es) Derivados de la indolizina como inhibidores de las fosfoinositido-3 quinasas
CO2017002506A2 (es) Nuevos activadores de la guanilato ciclasa soluble y su uso
AR101414A1 (es) Derivados de pirrolidinona como inhibidores de metap-2
DOP2016000297A (es) Composiciones farmacéuticas útiles para tratar enfermedades infecciosas
MX2017013137A (es) Derivados de cromeno como inhibidores de las fosfoinositido-3-cina sas.
UY36070A (es) Triterpenoides con actividad inhibidora de la maduración de hiv
CO2017002813A2 (es) Derivados estabilizados de adrenomedulina y uso de los mismos
ECSP13012988A (es) Derivados de tienopirimidina (2,3-d) y su uso para tratar arritmia
GEP20196957B (en) Crystalline forms of s-acetyl glutathione, their reparations and uses in pharmaceutical and nutraceutical formulations
CO2017002963A2 (es) Espiro-tiazolonas
NZ739679A (en) Cholecalciferol sulfate salts and their use for the treatment of vitamin d deficiency
CL2018000349A1 (es) 5-bromo-2,6-di-(1h-pyrazol-1-il) pyrimidin-4-amina para uso en el tratamiento del cancér.
ECSP17063489A (es) Derivados de nucleósidos sustituidos útiles como agentes antineoplásicos
UY34803A (es) ?compuestos reguladores del crecimiento vegetal,composiciones que los comprenden, métodos para promover germinación y crecimiento, material vegetal y sus usos?
AR101915A1 (es) Intermediarios y procesos para la preparación de compuestos